4 Firms Advise On Genmab's $8B Merus Acquisition Plan
Genmab AS announced Monday it has agreed to purchase Dutch clinical-stage biotechnology firm Merus NV in an all-cash transaction valued at about $8 billion, with Allen Overy Shearman Sterling and Kromann...To view the full article, register now.
Already a subscriber? Click here to view full article